Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 3/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | FAP | Q12884 | 1/20 | 0.40 |
| ▸ | CALCRL | Q16602 | 2/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
| ▸ | MASP2 | O00187 | 2/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | PRCP | P42785 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30697798 | 1.00 | PREP (0.40) | PREPDPP4FAPCALCRLACE | |
| SCHEMBL29568547 | 0.92 | ACE (0.41) | PREPDPP4FAPACEMASP2 | |
| SCHEMBL29474450 | 0.91 | ACE (0.40) | PREPDPP4FAPACEF2 | |
| SCHEMBL29474448 | 0.91 | ACE (0.40) | PREPDPP4FAPACEF2 | |
| SCHEMBL29308708 | 0.89 | PREP (0.37) | PREPDPP4FAPCALCRLACE | |
| SCHEMBL30633419 | 0.86 | PREP (0.40) | PREPDPP4FAPACEDPP7 | |
| SCHEMBL29396785 | 0.86 | DPP7 (0.46) | MASP2DPP7F2PRCP | |
| SCHEMBL31518665 | 0.84 | ACE (0.46) | ACEDPP7F2PRCP | |
| SCHEMBL30434146 | 0.84 | REN (0.49) | CALCRLACEPSMB9 | |
| SCHEMBL31564810 | 0.84 | FAP (0.44) | PREPDPP4FAPCALCRLACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115261-A1 | COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS AND USES THEREOF | SUSTAIN HOLDINGS LLC (US) | 2026-04-30 | — | — | US | disclosed |
| CN-119698289-A | Pharmaceutical composition based on collagen peptide and application thereof | 莎思坦控股有限责任公司 | 2025-03-25 | — | — | CN | disclosed |
| US-20240016900-A1 | COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS AND USES THEREOF | SUSTAIN HOLDINGS, LLC | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115261-A1 | COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS AND USES THEREOF | COL1A1, COL2A1, COL14A1 | PREP 346/4885DPP4 852/4885FAP 664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.